Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Accumulated Expenses (2017 - 2024)

Solid Biosciences' Accumulated Expenses history spans 8 years, with the latest figure at $13.2 million for Q3 2024.

  • For Q3 2024, Accumulated Expenses rose 15.36% year-over-year to $13.2 million; the TTM value through Sep 2024 reached $13.2 million, up 15.36%, while the annual FY2023 figure was $10.2 million, 39.12% down from the prior year.
  • Accumulated Expenses for Q3 2024 was $13.2 million at Solid Biosciences, up from $9.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $16.7 million in Q4 2022 and bottomed at $6.8 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $9.9 million (2024), against an average of $10.3 million.
  • The largest annual shift saw Accumulated Expenses soared 109.24% in 2022 before it tumbled 39.12% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $8.6 million in 2020, then increased by 10.28% to $9.5 million in 2021, then surged by 75.18% to $16.7 million in 2022, then crashed by 39.12% to $10.2 million in 2023, then skyrocketed by 30.17% to $13.2 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Accumulated Expenses are $13.2 million (Q3 2024), $9.9 million (Q2 2024), and $10.3 million (Q1 2024).